-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the increasing number of diabetic patients, as an important means of clinical treatment of diabetes, the market scale of insulin drugs has continued to expand
.
Statistics show that in 2019, the domestic diabetes drug market has reached approximately 32.
3 billion yuan, of which the insulin market has nearly 20 billion yuan
.
In 2020, the sales of insulin and similar drugs in China's public medical institutions have reached about 27 billion yuan, a year-on-year increase of 7.
9%
.
Insulin national procurement is about to start (picture source: Pharmaceutical Network).
It is worth noting that under the influence of factors such as the continuous expansion of the market and the clarity of the relationship between the use of various insulin categories, the continuous increase in the number of manufacturers, and the fierce market competition, insulin When to enter the national procurement has also gradually become the focus of people's attention
.
At present, the above questions have finally ushered in answers
.
On September 13, the National Organization for Drug Joint Procurement Office officially issued a notice on reporting the sixth batch of nationally organized drug procurement (insulin special) medical institutions
.
Judging from the notice, the products for this centralized purchase of drugs are second-generation insulin and third-generation insulin, which are divided into 3 groups according to meal time, basis, and premix, for a total of 6 purchase groups
.
Data reporting is done online, and the medical institution reports the historical purchase volume and purchase demand volume based on the company’s products
.
The industry believes that the advent of national procurement of insulin means that there will be more room for domestically produced insulin to replace imported insulin.
While the entire market structure is undergoing dramatic changes, a large number of local pharmaceutical companies may also usher in more development opportunities
.
It is worth mentioning that in addition to related pharmaceutical companies, some insiders believe that insulin production equipment companies will also benefit
.
This is mainly because centralized procurement generally trades price for volume.
After the relevant pharmaceutical companies win the bid, they often need to increase their production capacity to meet market demand; in this context, more efficient and safer insulin production equipment is also required.
It has naturally become a hot spot for pharmaceutical companies
.
In fact, many companies have already begun to build and upgrade insulin production lines to further ensure that the quality of related products is controllable, safe and effective. .
For example, there is a high-tech biopharmaceutical company that focuses on investment in the field of diabetes and built an "oral insulin capsule production line" by introducing international technology in 2019
.
The production line is designed and built in accordance with the GMP standards of China's NMPA, the US FDA, and the European Medicines Agency (EMA).
It covers an area of 3000 square meters.
It has professional protein purification and separation production equipment, automatic soft capsule production lines, coating production lines, and packaging production lines.
And high-standard quality control system
.
The equipment has a high degree of automation, stable and reliable operation performance, and can effectively ensure the quality and safety of oral insulin capsules
.
In addition, in recent years, in order to promote the high-quality development of the pharmaceutical industry, the country has been advocating green production
.
However, it should be noted that the wastewater produced by insulin has always had problems such as complex composition, high concentration of organic matter, and high salinity, and it needs to be treated before it can be discharged or continue to be used
.
Therefore, in order to meet environmental protection requirements, the demand for wastewater treatment equipment by relevant pharmaceutical companies will further increase, and this will also bring more opportunities for relevant equipment companies
.
In general, the pharmaceutical equipment industry is closely related to pharmaceutical companies.
With the continuous expansion of the insulin market and the further increase in concentration, it is bound to have a lot to do
.
However, it should be noted that the performance and technical level of equipment are always the focus of pharmaceutical companies.
Therefore, pharmaceutical equipment companies also need to continuously improve their innovation capabilities and technologies to develop higher-quality and safer equipment.
Meet the increasing quality requirements of insulin companies and help them develop in compliance
.
.
Statistics show that in 2019, the domestic diabetes drug market has reached approximately 32.
3 billion yuan, of which the insulin market has nearly 20 billion yuan
.
In 2020, the sales of insulin and similar drugs in China's public medical institutions have reached about 27 billion yuan, a year-on-year increase of 7.
9%
.
Insulin national procurement is about to start (picture source: Pharmaceutical Network).
It is worth noting that under the influence of factors such as the continuous expansion of the market and the clarity of the relationship between the use of various insulin categories, the continuous increase in the number of manufacturers, and the fierce market competition, insulin When to enter the national procurement has also gradually become the focus of people's attention
.
At present, the above questions have finally ushered in answers
.
On September 13, the National Organization for Drug Joint Procurement Office officially issued a notice on reporting the sixth batch of nationally organized drug procurement (insulin special) medical institutions
.
Judging from the notice, the products for this centralized purchase of drugs are second-generation insulin and third-generation insulin, which are divided into 3 groups according to meal time, basis, and premix, for a total of 6 purchase groups
.
Data reporting is done online, and the medical institution reports the historical purchase volume and purchase demand volume based on the company’s products
.
The industry believes that the advent of national procurement of insulin means that there will be more room for domestically produced insulin to replace imported insulin.
While the entire market structure is undergoing dramatic changes, a large number of local pharmaceutical companies may also usher in more development opportunities
.
It is worth mentioning that in addition to related pharmaceutical companies, some insiders believe that insulin production equipment companies will also benefit
.
This is mainly because centralized procurement generally trades price for volume.
After the relevant pharmaceutical companies win the bid, they often need to increase their production capacity to meet market demand; in this context, more efficient and safer insulin production equipment is also required.
It has naturally become a hot spot for pharmaceutical companies
.
In fact, many companies have already begun to build and upgrade insulin production lines to further ensure that the quality of related products is controllable, safe and effective. .
For example, there is a high-tech biopharmaceutical company that focuses on investment in the field of diabetes and built an "oral insulin capsule production line" by introducing international technology in 2019
.
The production line is designed and built in accordance with the GMP standards of China's NMPA, the US FDA, and the European Medicines Agency (EMA).
It covers an area of 3000 square meters.
It has professional protein purification and separation production equipment, automatic soft capsule production lines, coating production lines, and packaging production lines.
And high-standard quality control system
.
The equipment has a high degree of automation, stable and reliable operation performance, and can effectively ensure the quality and safety of oral insulin capsules
.
In addition, in recent years, in order to promote the high-quality development of the pharmaceutical industry, the country has been advocating green production
.
However, it should be noted that the wastewater produced by insulin has always had problems such as complex composition, high concentration of organic matter, and high salinity, and it needs to be treated before it can be discharged or continue to be used
.
Therefore, in order to meet environmental protection requirements, the demand for wastewater treatment equipment by relevant pharmaceutical companies will further increase, and this will also bring more opportunities for relevant equipment companies
.
In general, the pharmaceutical equipment industry is closely related to pharmaceutical companies.
With the continuous expansion of the insulin market and the further increase in concentration, it is bound to have a lot to do
.
However, it should be noted that the performance and technical level of equipment are always the focus of pharmaceutical companies.
Therefore, pharmaceutical equipment companies also need to continuously improve their innovation capabilities and technologies to develop higher-quality and safer equipment.
Meet the increasing quality requirements of insulin companies and help them develop in compliance
.